🔎 Trials Near Me

Home › Meningioma › Georgia

Pag-aaral pangklinika para sa Meningioma sa Georgia

6 pag-aaral para sa Meningioma ang naghahanap ng mga kalahok sa mga site sa Georgia.

Mga Lungsod sa Georgia

Opisyal na teksto ng pag-aaral (English)

Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

  • Grady Health System, Atlanta
  • Emory Proton Therapy Center, Atlanta
  • Piedmont Hospital, Atlanta
  • at 5 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 10, 2026 · NCT03180268

Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment

  • Piedmont Healthcare, Atlanta
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 8, 2026 · NCT06955169

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

  • Grady Health System, Atlanta
  • Emory University Hospital Midtown, Atlanta
  • Piedmont Hospital, Atlanta
  • at 1 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT02523014

Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)

  • Piedmont Healthcare, Atlanta
  • Winship Cancer Institute of Emory University, Atlanta
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Hul 22, 2026 · NCT04427384

Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study

  • Emory University Hospital/Winship Cancer Institute, Atlanta
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 17, 2026 · NCT04278118

Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial

  • Emory University Hospital/Winship Cancer Institute, Atlanta
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 10, 2026 · NCT06132685

Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.